Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Neuroscientific Biopharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $5.64 million
P/E Ratio 15.45
Dividend Yield 0.00%
Shares Outstanding 144.60 million
Earnings per share 0.005
Dividend per share N/A
Year To Date Return -13.64%
Earnings Yield 6.47%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Neuroscientific Biopharmaceuticals Ltd (ASX: NSB)
    Latest News

    rising medical asx share price represented by excited doctors dancing in ward
    Healthcare Shares

    Here are the 5 best performing ASX biotech shares of 2021

    It was a rollercoaster year on the ASX for the biotechnology sector. We take a look at the top performers

    Read more »

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Healthcare Shares

    Neuroscientific Biopharmaceuticals (ASX:NSB) share price surges 11% on drug update

    This drug candidate is showing real promise. Let's take a closer look

    Read more »

    Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares
    Share Gainers

    These 3 ASX Healthcare shares have soared over 10% today

    The three healthcare shares are well on the rise today. Read on for more details.

    Read more »

    jump in asx share price represented by man leaping up from one wooden pillar to the next
    Share Gainers

    Neuroscientific Biopharmaceuticals (ASX:NSB) share price leaps 11% on study update

    This comes after the release of an announcement. Let's take a further look.

    Read more »

    health worker wearing personal protective equipment and gesturing stop with her hands
    Share Market News

    Neuroscientific Biopharmaceuticals (ASX:NSB) share price jumps 9% before trading halt

    It's been an interesting day on the ASX for the Australian biotech company. Here are the details

    Read more »

    falling healthcare asx share price Mesoblast capital raising
    Healthcare Shares

    NeuroScientific Biopharmaceuticals (ASX:NSB) share price wobbles on study results

    The company's shares reached an intraday high of 36 cents before retreating.

    Read more »

    illustration of half brain half lightbulb
    Share Market News

    This ASX biotech share is up 20% today

    A positive preliminary study helped send this ASX biotech share surging 50% before it edged back to a more modest…

    Read more »

    a woman
    Share Market News

    Why this ASX microcap skyrocketed 190% on Tuesday

    The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price is up 190% on news of a spinal injury breakthrough

    Read more »

    NSB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Neuroscientific Biopharmaceuticals Ltd

    Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies.

    NSB Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    09 Oct 2024 $0.04 $0.00 0.00% 333,705 $0.04 $0.04 $0.04
    08 Oct 2024 $0.04 $0.00 0.00% 185,055 $0.04 $0.04 $0.04
    07 Oct 2024 $0.04 $0.00 0.00% 113,163 $0.04 $0.04 $0.04
    04 Oct 2024 $0.04 $0.00 0.00% 298,077 $0.04 $0.04 $0.04
    03 Oct 2024 $0.04 $0.00 0.00% 392,234 $0.04 $0.04 $0.04
    02 Oct 2024 $0.04 $0.00 0.00% 292,594 $0.04 $0.04 $0.04
    01 Oct 2024 $0.04 $0.00 0.00% 1,896,770 $0.03 $0.04 $0.03
    30 Sep 2024 $0.04 $0.00 0.00% 144,279 $0.03 $0.04 $0.03
    27 Sep 2024 $0.03 $0.00 0.00% 608,089 $0.04 $0.04 $0.03
    26 Sep 2024 $0.04 $0.00 0.00% 51,536 $0.04 $0.04 $0.04
    25 Sep 2024 $0.04 $0.00 0.00% 25,000 $0.04 $0.04 $0.04
    18 Sep 2024 $0.04 $0.00 0.00% 113,665 $0.04 $0.04 $0.04
    17 Sep 2024 $0.04 $0.00 0.00% 161,800 $0.04 $0.04 $0.03
    16 Sep 2024 $0.04 $0.00 0.00% 95,000 $0.03 $0.04 $0.03
    12 Sep 2024 $0.04 $0.00 0.00% 130 $0.04 $0.04 $0.04
    11 Sep 2024 $0.04 $0.00 0.00% 1,415,720 $0.04 $0.04 $0.03
    10 Sep 2024 $0.04 $0.00 0.00% 199,708 $0.04 $0.04 $0.04

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Anton Uvarov Non-Executive Director Nov 2022
    Dr Uvarov has experience as an equity analyst in the healthcare industry with a focus on the biotechnology sector, both domestically and internationally.
    Mr Christopher Ntoumenopoulos Non-Executive DirectorNon-Executive Chairman Nov 2023
    Mr Ntoumenopoulos is the Managing Director at Twenty 1 Corporate, an Australian-based corporate advisory firm. Mr Ntoumenopoulos has experience in financial markets, with over 20 years of raising capital and providing corporate advisory services.
    Dr Anthony (Tony) Keating Executive Director Dec 2023
    Dr Keating is an experienced entrepreneur and CEO, having co-founded and led ResApp Health Ltd from start-up to its ultimate acquisition by Pfizer for $180 million.
    Mr Clarke Barlow Non-Executive Director Nov 2023
    Mr Barlow is a Financial Adviser and Capital Markets Specialist with over 20 years of experience in the Financial Services Industry in Australia and the United Kingdom. Mr Barlow has experience providing corporate advisory services for companies listed on the ASX across a variety of industries, with a particular focus on growth opportunities in the biotechnology, technology, industrial and resources industries.
    Dr Linda Friedland Non-Executive Director Oct 2023
    Dr Friedland with over 25 years of experience in clinical medicine and an international advisor to many Fortune and Forbes global companies. She consults with healthcare, biotech, corporate, and financial insitutions. Linda is a non-executive director on several Healthcare boards within Australia and abroad. Among her roles, Dr Friedland is Deputy Chairman of the Neurological Council of Western Australia (NCWA), senior consultant to TargImmune Therapeutics (Basel, Switzerland), co-founder and director of FFD Capital LLC (USA) and Asia- Pacific partner for Camelot BioCapital. An author of seven healthcare-related bestsellers with a career in television and health media, she has developed public health and disease management programs in Asia, USA, Australia, Africa, and the UK and delivered keynote addresses in more than 30 countries
    Mr Christopher (Chris) Bryan Achurch Company Secretary Feb 2024
    -
    Christopher (Chris) Bryan Achurch Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    MCRAE Technology Pty Ltd 19,122,262 13.22%
    BNP Paribas Noms Pty Ltd <Drp> 17,780,425 12.30%
    MCRAE Investments Pty Ltd 4,985,659 3.45%
    Utas Holdings Pty Ltd 3,954,123 2.73%
    Citicorp Nominees Pty Limited 3,393,062 2.35%
    Lehav Pty Ltd <The Vhl Family A/C> 2,872,644 1.99%
    ECU Holdings Pty Ltd 2,555,556 1.77%
    HSBC Custody Nominees (Australia) Limited 2,107,712 1.46%
    Mr Edward Joseph & Mrs Margaret Mary Gettingby 2,090,000 1.45%
    Ms Yulia Uvarova 2,000,000 1.38%
    Whale Watch Holdings Limited 1,927,341 1.33%
    Mr Mohammed Akbar Asem 1,770,183 1.22%
    Mr Edward Joseph & Mrs Margaret Mary Gettingby i 1,703,333 1.18%
    Solequest Pty Ltd 1,601,422 1.11%
    Dossman Pty Ltd 1,595,666 1.10%
    Ice Lake Investments Pty Ltd 1,550,000 1.07%
    Trevor Borrows Investment Pty Ltd 1,500,000 1.04%
    Aukera Capital Pty Ltd <Aukera Discretionary A/C> 1,200,000 0.83%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 1,153,551 0.80%
    Mr Paul John Rennie 1,090,753 0.75%

    Profile

    since

    Note